FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutics and medicine, and concerns protein and peptide stabilisation formulation which contains a hydrophilic polymer, a mixture of polyalcohol and sugar, wherein a weight ratio of polyalcohol to sugar makes from 2:1 to 5:1 (wt %), a detergent, and wherein the formulation is free from stabilising proteins. A composition and a kit for treating a disease or a composition caused by hyperactive cholinergic innervation of muscles or endocrine glands in a patient, and contain the above formulation and peptide, protein or a mixture thereof.
EFFECT: group of inventions provides the better protein stability in the absence of stabilising proteins.
13 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE | 2009 |
|
RU2524429C2 |
| HIGH INTRODUCTION RATE OF NEUROTOXIC COMPONENT OF BOTULINUM TOXIN | 2007 |
|
RU2453333C2 |
| PHARMACEUTICAL COMPOSITIONS OF CLOSTRIDIA TOXIN | 2009 |
|
RU2535003C2 |
| LIQUID COMPOSITION STABILIZING BOTULINUM TOXIN | 2019 |
|
RU2812790C2 |
| PROCESS FOR PREPARING HIGHLY PURE NEUROTOXIC COMPONENT OF BOTULINUM TOXIN AND USES THEREOF | 2014 |
|
RU2663136C2 |
| COMPOSITION FOR PROTEIN PHARMACEUTICAL PREPARATION WITH NO ADDED HUMAN SERUM ALBUMIN (HSA) | 2004 |
|
RU2491927C2 |
| COMPOSITION FOR PROTEIN PHARMACEUTICAL MEDICATION WITHOUT ADDITION OF HUMAN SERUM ALBUMEN (HSA) | 2004 |
|
RU2354366C2 |
| STABILIZED NON-PROTEIN COMPOSITIONS OF CLOSTRIDIAL TOXIN | 2017 |
|
RU2762607C2 |
| BOTULINUM TOXIN CONTAINING COMPOSITION | 2017 |
|
RU2743746C2 |
| METHOD OF OBTAINING BOTULINUM NEUROTOXIN (VERSIONS) | 2010 |
|
RU2561459C2 |
